Table 1.
Baseline characteristics of the study participants who underwent TACE.
| Characteristics | Value |
|---|---|
| Patients, N | 611 |
| Age, mean ± SD | 61.43 ± 10.90 |
| Gender male, N (%) | 445 (72.8) |
| Body mass index (kg/m2) | |
| < 20.0 (underweight), N (%) | 106 (17.3) |
| 20.0–24.9 (normal weight), N (%) | 305 (50.0) |
| ≥ 25.0 (overweight/obese), N (%) | 200 (32.7) |
| Etiology, N (%) | |
| HBV/HCV/HBV + HCV/Alcohol/others | 301 (49.3)/135 (22.1)/7 (1.1)/65 (10.6)/103 (16.9) |
| Comorbidity, N (%) | |
| Diabetes | 169 (27.7) |
| Hypertension | 166 (27.2) |
| Cardiovascular disease | 39 (6.4) |
| Pulmonary disease | 35 (5.7) |
| Chronic kidney disease | 26 (4.3) |
| Child–Pugh class, N (%) | |
| A/B | 465 (76.1)/146 (23.9) |
| AST (IU/L), median (IQR) | 61.0 (42.0,88.0) |
| ALT (IU/L), median (IQR) | 38.0 (25.0,61.0) |
| Total bilirubin (mg/dL), median (IQR) | 0.81 (0.53,1.32) |
| Albumin (g/dL), mean ± SD | 3.53 ± 0.54 |
| Platelet count (× 103/mm3), median (IQR) | 116 (74,189) |
| BCLC-staging, N (%) | |
| A/B/C | 172 (28.2)/406 (66.4)/33 (5.4) |
| Alpha-fetoprotein (ng/mL), N (%) | |
| < 200, ≥ 200 | 418 (68.4)/193 (31.6) |
| Tumor size (cm), N (%) | |
| ≤ 3, 3–5, > 5 | 171 (28.0)/173 (28.3)/267 (43.7) |
| Number of tumors, N (%) | |
| 1, 2–3, > 3 | 257 (42.0)/188 (30.8)/166 (27.2) |
| TACE sessions, median (IQR) | 2 (1–4) |
| SMI (cm2/m2), median (IQR) | |
| Male | 39.9 (34.8,44.6) |
| Female | 30.5 (27.0,34.3) |
| SMD (HU), median (IQR) | |
| Male | 46.0 (41.9,50.2) |
| Female | 39.7 (35.0,43.3) |
SD standard deviation, IQR interquartile range, HBV hepatitis B virus, HCV hepatitis C virus, AST aspartate transaminase, ALT alanine transaminase, BCLC Barcelona Clinic Liver Cancer, TACE transarterial chemoembolization, SMI skeletal muscle index, SMD skeletal muscle density.